Research ArticleAlzheimer’s Disease

APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function

See allHide authors and affiliations

Science Translational Medicine  17 Feb 2021:
Vol. 13, Issue 581, eabd7522
DOI: 10.1126/scitranslmed.abd7522

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Controlling amyloid in brain and vasculature

The genetic variant ε4 of the gene APOE (APOE4) is associated with increased risk of developing Alzheimer’s disease (AD). In AD, Aβ forms deposits in the brain parenchyma (amyloid plaques) and in the cerebral vasculature [cerebral amyloid angiopathy (CAA)]. Immunotherapy targeting human APOE reduced brain Aβ deposits in mice. Now, Xiong et al. used a mouse model with both amyloid plaques and CAA and evaluated the effects of the anti-human APOE antibody HAE-4. The treatment reduced both parenchymal Aβ plaques and CAA without vascular complications, whereas an antibody targeting Aβ exacerbated CAA-related microhemorrhages. The results suggest that HAE-4 may provide therapeutic effects on amyloid removal in AD while protecting the cerebrovasculature.

View Full Text

Stay Connected to Science Translational Medicine